Compare BRBI & IMRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BRBI | IMRX |
|---|---|---|
| Founded | 2009 | 2008 |
| Country | Brazil | United States |
| Employees | N/A | N/A |
| Industry | Finance: Consumer Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 293.2M | 313.8M |
| IPO Year | 2025 | 2021 |
| Metric | BRBI | IMRX |
|---|---|---|
| Price | $11.36 | $4.57 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 5 |
| Target Price | N/A | ★ $17.20 |
| AVG Volume (30 Days) | 930.0 | ★ 632.6K |
| Earning Date | 05-08-2026 | 05-04-2026 |
| Dividend Yield | ★ 5.03% | N/A |
| EPS Growth | N/A | ★ 37.75 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $17.24 | N/A |
| P/E Ratio | $11.72 | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $9.09 | $3.86 |
| 52 Week High | $67.01 | $10.08 |
| Indicator | BRBI | IMRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.80 | 40.82 |
| Support Level | $10.90 | $4.49 |
| Resistance Level | $11.97 | $5.32 |
| Average True Range (ATR) | 0.11 | 0.20 |
| MACD | 0.28 | -0.07 |
| Stochastic Oscillator | 94.34 | 13.54 |
BRBI BR Partners SA, formerly BR Advisory Partners Participacoes SA, is engaged in investing in other companies, domestic or foreign, as a partner, quota holder, or shareholder, and management of its assets. It has a single reportable segment being investment banking services, which are administered and managed according to the products offered. However, the company divides it's operations into the following business lines: (1) investment banking and capital markets, (2) treasury sales & structuring, (3) investments and wealth management and (4) capital remuneration.
Immuneering Corp is a biopharmaceutical company. It is focused on improving patient outcomes across a spectrum of debilitating oncologic and neurologic diseases by applying deep knowledge of translational bioinformatics to every stage of the drug development process. The company's proprietary computational Disease Cancelling Technology platform enables Immuneering's drug discovery programs. The company also provides unparalleled computational biology capabilities to pharmaceutical and biotechnology companies.